NASDAQ:CORT

Corcept Therapeutics Stock Forecast, Price & News

$22.37

+0.41 (+1.87 %)

(As of 06/23/2021 12:59 PM ET)

Add

Compare

Today's Range

$21.95

▼

$22.42

50-Day Range

$19.97

▼

$24.31

52-Week Range

$12.20

▼

$31.18

Volume8,885 shs

Average Volume582,073 shs

Market Capitalization$2.61 billion

P/E Ratio28.68

Dividend YieldN/A

Beta0.73

30 days | 90 days | 365 days | Advanced Chart

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Corcept Therapeutics

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics (NASDAQ:CORT) Price Target Lowered to $29.00 at HC Wainwright
June 23, 2021 | americanbankingnews.com

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
June 22, 2021 | finance.yahoo.com

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 22, 2021 | finance.yahoo.com

Corcept Therapeutics (NASDAQ:CORT) Shares Gap Down to $22.98
June 22, 2021 | americanbankingnews.com

Corcept Therapeutics' (CORT) "Positive" Rating Reaffirmed at UBS Group
June 22, 2021 | americanbankingnews.com

Corcept's Relacorilant fails To Show Substantial Benefit In Metastatic Pancreatic Cancer Trial
June 22, 2021 | markets.businessinsider.com

Are Insiders Buying Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock?
June 17, 2021 | finance.yahoo.com

CORT Makes Bullish Cross Above Critical Moving Average
June 16, 2021 | nasdaq.com

G Leonard Baker, Jr. Buys 50,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock
June 15, 2021 | americanbankingnews.com

Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 15, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
Previous Symbol
CUSIP21835210
CIK1088856
Webwww.corcept.com
Phone650-327-3270
Employees236
Year FoundedN/A

Sales & Book Value

Annual Sales$353.87 million
Price / Sales7.37
Cash Flow$0.98 per share
Price / Cash Flow22.83
Book Value$4.50 per share
Price / Book4.97

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares116,631,000
Market Cap$2.61 billion
Next Earnings Date8/3/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.81 out of 5 stars

Medical Sector

196th out of 2,105 stocks

Pharmaceutical Preparations Industry

92nd out of 832 stocks

1.3 Analyst's Opinion

Consensus Rating
Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.50, Corcept Therapeutics has a forecasted upside of 1.4% from its current price of $22.20.
Amount of Analyst Coverage
Corcept Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Corcept Therapeutics has received 477 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Corcept Therapeutics has received 404 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Corcept Therapeutics has received 54.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote “Outperform” if you believe CORT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Corcept Therapeutics does not currently pay a dividend.
Dividend Growth
Corcept Therapeutics does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corcept Therapeutics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $1,076,500.00 in company stock and sold $1,179,350.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
Only 16.40% of the stock of Corcept Therapeutics is held by insiders.
Percentage Held by Institutions
69.37% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Corcept Therapeutics are expected to grow by 25.64% in the coming year, from $0.78 to $0.98 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corcept Therapeutics is 28.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.59.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corcept Therapeutics is 28.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.92.
Price to Earnings Growth Ratio
Corcept Therapeutics has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Corcept Therapeutics has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

Is Corcept Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corcept Therapeutics stock.
View analyst ratings for Corcept Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Corcept Therapeutics?

Wall Street analysts have given Corcept Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corcept Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Corcept Therapeutics.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported $0.18 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.03. The biotechnology company had revenue of $79.44 million for the quarter, compared to the consensus estimate of $96.99 million. Corcept Therapeutics had a trailing twelve-month return on equity of 20.11% and a net margin of 29.23%. The firm's revenue was down 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 EPS.
View Corcept Therapeutics' earnings history.

How has Corcept Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CORT stock has increased by 104.7% and is now trading at $22.41.
View which stocks have been most impacted by COVID-19.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $355 million-$385 million, compared to the consensus revenue estimate of $396.20 million.

What price target have analysts set for CORT?

3 brokerages have issued 12-month target prices for Corcept Therapeutics' stock. Their forecasts range from $16.00 to $29.00. On average, they expect Corcept Therapeutics' stock price to reach $22.50 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Corcept Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:

Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 64, Pay $1.52M)
Dr. Hazel Hunt, Chief Scientific Officer
Mr. Sean Maduck, Chief Commercial Officer (Age 44, Pay $688.54k)
Dr. Andreas Grauer M.D., Chief Medical Officer (Age 60, Pay $791.98k)
Mr. Gary Charles Robb, Chief Bus. Officer & Sec. (Age 58, Pay $795.62k)
Mr. Atabak Mokari, Chief Financial Officer (Age 44)
Mr. Joseph Douglas Lyon, Chief Accounting Officer (Age 42)
Dr. Christopher Shayne James M.D., Director of Investor Relations
Donald E. Laferle, Sr. VP

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics CEO Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among Corcept Therapeutics' employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corcept Therapeutics' key competitors?

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of CORT's competitors.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (13.87%), Renaissance Technologies LLC (7.52%), Ingalls & Snyder LLC (5.92%), Dimensional Fund Advisors LP (2.24%), Geode Capital Management LLC (1.52%) and Parallel Advisors LLC (1.33%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics.

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ingalls & Snyder LLC, LSV Asset Management, D. E. Shaw & Co. Inc., Jupiter Asset Management Ltd., Voloridge Investment Management LLC, Goldman Sachs Group Inc., and Schroder Investment Management Group. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, Gary Charles Robb, Joseph Douglas Lyon, and Sean Maduck.
View insider buying and selling activity for Corcept Therapeutics or view top insider-selling stocks.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Trust Walden Corp, AJ Wealth Strategies LLC, Allianz Asset Management GmbH, TD Asset Management Inc., Geode Capital Management LLC, BI Asset Management Fondsmaeglerselskab A S, and Morgan Stanley. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, and G Leonard Baker, Jr.
View insider buying and selling activity for Corcept Therapeutics or or view top insider-buying stocks.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $22.41.

How much money does Corcept Therapeutics make?

Corcept Therapeutics has a market capitalization of $2.61 billion and generates $353.87 million in revenue each year. The biotechnology company earns $106.01 million in net income (profit) each year or $0.85 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

Corcept Therapeutics employs 236 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

Where are Corcept Therapeutics' headquarters?

Corcept Therapeutics is headquartered at 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here